Results 181 to 190 of about 40,969 (293)

Theranostics and molecular imaging are taking off: current situation, requirements and how to train more physicians to fill the gap. A perspective from three different continents. [PDF]

Br J Radiol
Veit-Haibach P, Lam W, Wong RKS, Cook GJR.   +3 more
europepmc   +1 more source

Bismuth-based nanosystems for precise tumor theranostics: Recent progress, challenges and perspectives. [PDF]

Theranostics
Zhang H, Guo M, Kong Z, Ma Y, Hong L, Pang M, Wang Z, Yang M, An J, Pak YL, Song J.   +10 more
europepmc   +1 more source

AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma

Medicinal Research Reviews, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo, Kaeun Chae, Jueun Lee, Inseon Kim, Seunghun S. Lee   +4 more
wiley   +1 more source

Uneven Global Distribution of Theranostics. [PDF]

World J Nucl Med
Kairemo K, Al-Ibraheem A.
europepmc   +1 more source

Aptamer–Based Targeted Protein Degradation: Mechanistic Principles, Delivery Strategies, and Translational Opportunities

Medicinal Research Reviews, EarlyView.
ABSTRACT Targeted elimination of pathogenic proteins remains a fundamental challenge in therapeutic intervention, particularly for proteins considered “undruggable” by conventional inhibition‐based approaches. Aptamer–based targeted protein degradation (TPD) has emerged as a versatile strategy that leverages the high specificity, structural ...
Ambrin Malik, Suyeon Son, Jaesung Lee, Ki Soo Park   +3 more
wiley   +1 more source

Artificial Intelligence in Nuclear Medicine (2015-2025): Clinical Applications, Regulatory Governance, and Pharmacotherapeutic Implications. [PDF]

Cureus
Alpizar-Rojas M, Jaromirski-Segura H, Herrera-Jiménez LG, Castro-Gamboa JA, Mora-Jiménez J, Arguedas-Chacón S, Zavaleta-Monestel E.   +6 more
europepmc   +1 more source

177Lu‐labeled amidoxime‐functionalized biodegradable microspheres for transarterial radioembolization of hepatocellular carcinoma

Precision Radiation Oncology, EarlyView.
Scheme 1. Schematic illustration of the synthesis and therapeutic evaluation of PLA‐g‐PAO microspheres (PLA‐g‐PAO‐Ms). Monodisperse PLA microspheres (PLA‐Ms) were initially fabricated via microfluidic technology. Surface grafting of acrylonitrile monomers was subsequently achieved through radiation‐induced graft polymerization, followed by ...
Xingliang Liu, Gang Wang, Zhenwen Zhao, Haoyu Wang, Hongyu Chen, Xiao Xu, Jingdong Li, Hongjuan Ma   +7 more
wiley   +1 more source

My Life as a "Theranostician": A commentary on the evolution of theranostics. [PDF]

Npj Imaging
Hicks RJ.
europepmc   +1 more source

C–X–C Motif Chemokine Receptor 4 (CXCR4)‐Targeted Biologically Guided Proton Spatially Fractionated Radiotherapy for Bulky Limited‐Stage Small Cell Lung Cancer

Precision Radiation Oncology, EarlyView.
A newly proposed proton spatially fractionated radiotherapy guided by biological imaging Abstract Background and Purpose To evaluate the feasibility and dosimetric safety of integrating C–X–C motif chemokine receptor 4 (CXCR4)‐targeted tracer 18F‐AlF‐NOTA‐QHY‐04 positron emission tomography imaging with biologically guided proton spatially fractionated
Keru Pu, Tengxiang Li, Shengnan Xu, Xue Sha, Qingtao Qiu, Jinming Yu, Yong Yin, Jie Liu   +7 more
wiley   +1 more source

Curcumin as theranostics: imaging-guided therapeutics in oncology and neurodegenerative diseases. [PDF]

Front Nutr
Yasir M, Maurya RK, Tripathi AS.
europepmc   +1 more source